AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)
Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%
AbbVie pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
AbbVie's pe ratio was 83.3× on Nov 11, 2026, against 172.5× a year earlier. Over the last 5 years it ranged from 19.0× to 173.1×, with a median of 61.7×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 83.3× | −89.8 |
| 2025 | Dec 31, 2025 | 173.1× | +111.4 |
| 2024 | Dec 31, 2024 | 61.7× | +19.2 |
| 2023 | Dec 29, 2023 | 42.5× | +20.9 |
| 2022 | Dec 30, 2022 | 21.6× | −10.7 |
| 2021 | Dec 31, 2021 | 32.2× | +9.6 |
| 2020 | Dec 31, 2020 | 22.7× | −18.1 |
| 2019 | Dec 31, 2019 | 40.8× | +21.8 |
| 2018 | Dec 31, 2018 | 19.0× | −4.5 |
| 2017 | Dec 29, 2017 | 23.5× | +6.6 |
| 2016 | Dec 30, 2016 | 16.9× | −18.1 |
| 2015 | Dec 31, 2015 | 35.1× | +6.6 |
| 2014 | Dec 31, 2014 | 28.5× | +9.9 |
| 2013 | Dec 31, 2013 | 18.6× | – |
See a number that looks wrong?